Format

Send to

Choose Destination
See comment in PubMed Commons below
Biometrics. 2000 Mar;56(1):271-8.

The impact of restrictive entry criterion during the placebo lead-in period.

Author information

1
Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana 46285, USA. richard.landin@wl.com

Abstract

In the study of depression, most randomized clinical trials have design features that attempt to sample from a stable patient population. One commonly used design feature is to require patients to maintain some minimum baseline symptom severity score during a placebo lead-in period. One intent of this design feature is to evaluate the behavior of patients prior to administration of active medication. If, during the lead-in period, patients do not maintain minimum symptom severity, the patients are excluded from the remainder of the study, the theory being that the excluded patients are not part of a stable patient population and hence are not likely to demonstrate efficacy of a truly effective treatment. This presentation investigates the effectiveness of a restrictive entry criterion and proposes an alternative explanation for what is usually defined as placebo response.

PMID:
10783806
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Support Center